MA42519A - Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique - Google Patents

Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Info

Publication number
MA42519A
MA42519A MA042519A MA42519A MA42519A MA 42519 A MA42519 A MA 42519A MA 042519 A MA042519 A MA 042519A MA 42519 A MA42519 A MA 42519A MA 42519 A MA42519 A MA 42519A
Authority
MA
Morocco
Prior art keywords
treatment
diabetic nephropathy
pde4 inhibitor
pde4
inhibitor
Prior art date
Application number
MA042519A
Other languages
English (en)
French (fr)
Inventor
Guido Hanauer
Masatoshi Hazama
Takanori Matsuo
Stephanie Vollert
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of MA42519A publication Critical patent/MA42519A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042519A 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique MA42519A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29

Publications (1)

Publication Number Publication Date
MA42519A true MA42519A (fr) 2018-06-06

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042519A MA42519A (fr) 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Country Status (9)

Country Link
US (1) US20200179369A1 (enExample)
EP (1) EP3328381A1 (enExample)
JP (1) JP2018521077A (enExample)
CN (1) CN108135886A (enExample)
BR (1) BR112018001116A2 (enExample)
CA (1) CA2992796A1 (enExample)
EA (1) EA201890346A1 (enExample)
MA (1) MA42519A (enExample)
WO (1) WO2017017165A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179384B2 (en) 2016-08-26 2021-11-23 Takeda Gmbh Treatment of nonalcoholic fatty liver disease
CN107157999A (zh) * 2017-05-27 2017-09-15 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281B (zh) * 2020-08-10 2025-05-27 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
EP2589599B1 (en) * 2004-03-03 2014-06-25 Takeda GmbH Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method

Also Published As

Publication number Publication date
JP2018521077A (ja) 2018-08-02
CA2992796A1 (en) 2017-02-02
EP3328381A1 (en) 2018-06-06
WO2017017165A1 (en) 2017-02-02
BR112018001116A2 (pt) 2018-09-11
EA201890346A1 (ru) 2018-08-31
US20200179369A1 (en) 2020-06-11
CN108135886A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3288592A4 (en) USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
EP3313325A4 (en) IMPLANTABLE EQUIPMENT FOR THE TREATMENT OF SINUSITIS
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3504187A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY
MA41449A (fr) Polythérapies pour le traitement de cancers
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3335041A4 (en) BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3383547A4 (en) ELECTROMAGNETIC MODULES FOR PROCESSING FLUIDS
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3351189A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
EP3503890A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA
EP3328374A4 (en) GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
EP3375108A4 (en) SELECTIVE WIFI
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3386967A4 (en) COMBINATIONS FOR TREATING KIDNEY STONES
EP3349793A4 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3309165A4 (en) SURFACE TREATMENT AGENT
EP3318205A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE